FreshRSS

Normální zobrazení

Jsou dostupné nové články, klikněte pro obnovení stránky.
PředevčíremHlavní kanál

Neuralink successfully implants its chip into a second patient's brain

Neuralink's brain chip has been implanted into a second patient as part of early human trials, Elon Musk told podcast host Lex Fridman on Saturday. The company hasn't disclosed when the surgery took place or the name of the recipient, according to Reuters.

Musk said 400 of the electrodes on the second patient's brain are working out of 1,024 implanted. "I don't want to jinx it but it seems to have gone extremely well," he said. "There's a lot of signal, a lot of electrodes. It's working very well." 

The device allows patients with spinal cord injuries to play video games, use the internet and control electronic devices using their thoughts alone. In May, the company announced that it was "accepting applications for the second participant" in trials following FDA approval. 

The original Neuralink implant patient, Nolan Arbaugh, described the surgery as "super easy." In a demo, the company showed how Arbaugh was able to move a cursor around the screen of a laptop, pause an on-screen music device and play chess and Civilization VI.

Arbaugh himself participated in the marathon podcast with Musk and Fridman. He said that the device allows him to make anything happen on a computer screen just by thinking it, helping reduce his reliance on caregivers. 

However, problems cropped up shortly after his surgery when some of electrodes retracted from his brain. The issue was partly rectified later on by modifying the algorithm to make the implants more sensitive. Neuralink told the FDA that in a second procedure, it would place the implant’s threads deeper into the patient’s brain to prevent them from moving as much as they did in Arbaugh’s case.

Neuralink previously tested its implant in animals, including chimps, and some of those testing practices have been the subject of federal investigations

Despite those issues, the company said it had over 1,000 volunteers for its second surgical trial. Musk said he expects Neuralink to implant its chips in up to eight more patients by the end of 2024.  

This article originally appeared on Engadget at https://www.engadget.com/neuralink-successfully-implants-its-chip-into-a-second-patients-brain-123013864.html?src=rss

© SOPA Images via Getty Images

POLAND - 2024/05/23: In this photo illustration, the Neuralink logo is seen displayed on a smartphone screen with a computer screen displaying a portrait of Elon Musk, who is the owner of Neuralink. The company is looking for new volunteers for its Neuralink implants. (Photo Illustration by Dominika Zarzycka/SOPA Images/LightRocket via Getty Images)

The world’s first tooth-regrowing drug has been approved for human trials

I remember being a kid and seeing my grandmother without her dentures for the first time. It was a harrowing experience. Now my dad has dentures so, genetically speaking, I’m several decades out from needing some myself. However, it’s possible that modern medicine will solve the issue of lost teeth by then, thanks to a new drug that's about to enter human trials.

The medicine quite literally regrows teeth and was developed by a team of Japanese researchers, as reported by New Atlas. The research has been led by Katsu Takahashi, head of dentistry and oral surgery at Kitano Hospital. The intravenous drug deactivates the uterine sensitization-associated gene-1 (USAG-1) protein that suppresses tooth growth. Blocking USAG-1 from interacting with other proteins triggers bone growth and, voila, you got yourself some brand-new chompers. Pretty cool, right?

Research news
New drug to regenerate lost teethhttps://t.co/qisOck4zt2#kyotouniversity #kyoto #japan #research #teeth

— Kyoto University (@KyotoU_News) April 13, 2021

Human trials start in September, but the drug has been highly successful when treating ferrets and mice and did its job with no serious side effects. Of course, the usual caveat applies. Humans are not mice or ferrets, though researchers seem confident that it’ll work on homo sapiens. This is due to a 97 percent similarity in how the USAG-1 protein works when comparing humans to other species.

September’s clinical trial will include adults who are missing at least one molar but there’s a secondary trial coming aimed at children aged two to seven. The kids in the second trial will all be missing at least four teeth due to congenital tooth deficiency. Finally, a third trial will focus on older adults who are missing “one to five permanent teeth due to environmental factors.”

Takahashi and his fellow researchers are so optimistic about this drug that they predict the medicine will be available for everyday consumers by 2030. So in six years we can throw our toothbrushes away and eat candy bars all day and all night without a care in the world (don’t actually do that.)

While this is the first drug that can fully regrow missing teeth, the science behind it builds on top of years of related research. Takahashi, after all, has been working on this since 2005. Recent advancements in the field include regenerative tooth fillings to repair diseased teeth and stem cell technology to regrow the dental tissue of children.

This article originally appeared on Engadget at https://www.engadget.com/the-worlds-first-tooth-regrowing-drug-has-been-approved-for-human-trials-174423381.html?src=rss

© Unsplash / Marek Studzinski

Some teeth.

Dr. Garmin will see you now

There’s a reason smartwatches haven’t replaced clinically validated gear when you visit the hospital — accuracy and reliability are paramount when the data informs medical procedures. Even so, researchers are looking for ways in which these devices can be meaningfully used in a clinical setting. One project in the UK has explored if a Garmin Venu 2 and dedicated companion app could be used to free up doctors and nurses, six minutes at a time.

The Six Minute Walk Test (6MWT) is used to diagnose and monitor a number of cardiovascular maladies. This includes conditions like Pulmonary Hypertension that, if left untreated, are eventually fatal. “[The test has been] a cornerstone of hospital practice and clinical trials for decades all around the world as [...] a marker of how well the heart and lungs are working,” project leader Dr. Joseph Newman told Engadget. While a change in a blood test marker might be clinically relevant, he said “it’s probably more important to someone that they can walk to the shop and back.” 

The test requires a patient walk on a flat, hard surface for six minutes straight, which stresses the heart enough to measure its capacity. A professional tests the patient’s heart rate and blood oxygen levels at the start and end. While it’s simple and reliable, "it’s not perfect,” according to Dr. Newman. “This is why we’ve looked to change it in two important ways," he said, "can we make it shorter [...] and digitize it for remote use?"

After all, six minutes is a lifetime in a clinical setting, and patients dislike having to schlep all the way to their hospital just to walk up and down a corridor. It’s why Newman and Lucy Robertson — both researchers at the Royal Papworth Hospital in Cambridge — began looking for ways to revolutionize the test. They wanted to see if the test could be shortened to a single minute, and also if it could be carried out by a patient at home using a Venu 2. 

The watch was connected to a secure and dedicated clinical trial platform built by Aparito – a Wrexham-based developer – for testing. This was then sent out to patients who were instructed to wear the watch and walk outdoors to complete their own tests. “They’re asked to walk on flat, even, dry, relatively straight roads rather than in laps or circuits,” Dr. Newman said, with patients walking at their own natural pace.

“We carried out a product appraisal early on in the research process and were open-minded as to the brand or model,” said Dr. Newman. “Garmin came out on top for a few reasons; we can access raw data as well as Garmin’s algorithmically-derived variables,” he said. Because the research was being funded by a charity, the British Heart Foundation, the watch had to offer good value for money. It helped that Garmin, with its established health research division, gave the team “confidence in the accuracy of the sensors,” not to mention the fact that Aparito feels that “the Garmin SDK is relatively easy to work with,” he added. 

But while Garmin is in use right now, there’s no reason this setup couldn’t eventually work with a number of other brands. “As long as the technology works, it’s accurate, reliable and patients accept it, then we’re not tied to any brand,” he said.

There are several benefits in giving patients the ability to run the tests at home: it’s more representative of the demands of their actual life, and patients can retake the test at regular intervals, making it easier to track that person’s health over time. “We can see real value in providing patients with pulmonary hypertension with an app and smartwatch to monitor their progress,” Dr. Newman said. “It’s unlikely to ever fully replace the need for in-person hospital reviews, but it will likely reduce their frequency.”

The results of the study right now suggest cutting the test to one minute has no detrimental effect on its outcome or accuracy, and that patients are far more likely to run the test regularly if they’re able to do so at home. “It’s likely that the upfront costs of wearables [to a hospital] may be offset by the longer term reduction in hospital visits,” Dr. Newman said. If that turns out to be right, it means clinicians can better focus their time and efforts where their expertise is more valuable.

This article originally appeared on Engadget at https://www.engadget.com/dr-garmin-will-see-you-now-160013340.html?src=rss

© Garmin

Product image of a Garmin Venu 2 on a white background.

Dr. Garmin will see you now

There’s a reason smartwatches haven’t replaced clinically validated gear when you visit the hospital — accuracy and reliability are paramount when the data informs medical procedures. Even so, researchers are looking for ways in which these devices can be meaningfully used in a clinical setting. One project in the UK has explored if a Garmin Venu 2 and dedicated companion app could be used to free up doctors and nurses, six minutes at a time.

The Six Minute Walk Test (6MWT) is used to diagnose and monitor a number of cardiovascular maladies. This includes conditions like Pulmonary Hypertension that, if left untreated, are eventually fatal. “[The test has been] a cornerstone of hospital practice and clinical trials for decades all around the world as [...] a marker of how well the heart and lungs are working,” project leader Dr. Joseph Newman told Engadget. While a change in a blood test marker might be clinically relevant, he said “it’s probably more important to someone that they can walk to the shop and back.” 

The test requires a patient walk on a flat, hard surface for six minutes straight, which stresses the heart enough to measure its capacity. A professional tests the patient’s heart rate and blood oxygen levels at the start and end. While it’s simple and reliable, "it’s not perfect,” according to Dr. Newman. “This is why we’ve looked to change it in two important ways," he said, "can we make it shorter [...] and digitize it for remote use?"

After all, six minutes is a lifetime in a clinical setting, and patients dislike having to schlep all the way to their hospital just to walk up and down a corridor. It’s why Newman and Lucy Robertson — both researchers at the Royal Papworth Hospital in Cambridge — began looking for ways to revolutionize the test. They wanted to see if the test could be shortened to a single minute, and also if it could be carried out by a patient at home using a Venu 2. 

The watch was connected to a secure and dedicated clinical trial platform built by Aparito – a Wrexham-based developer – for testing. This was then sent out to patients who were instructed to wear the watch and walk outdoors to complete their own tests. “They’re asked to walk on flat, even, dry, relatively straight roads rather than in laps or circuits,” Dr. Newman said, with patients walking at their own natural pace.

“We carried out a product appraisal early on in the research process and were open-minded as to the brand or model,” said Dr. Newman. “Garmin came out on top for a few reasons; we can access raw data as well as Garmin’s algorithmically-derived variables,” he said. Because the research was being funded by a charity, the British Heart Foundation, the watch had to offer good value for money. It helped that Garmin, with its established health research division, gave the team “confidence in the accuracy of the sensors,” not to mention the fact that Aparito feels that “the Garmin SDK is relatively easy to work with,” he added. 

But while Garmin is in use right now, there’s no reason this setup couldn’t eventually work with a number of other brands. “As long as the technology works, it’s accurate, reliable and patients accept it, then we’re not tied to any brand,” he said.

There are several benefits in giving patients the ability to run the tests at home: it’s more representative of the demands of their actual life, and patients can retake the test at regular intervals, making it easier to track that person’s health over time. “We can see real value in providing patients with pulmonary hypertension with an app and smartwatch to monitor their progress,” Dr. Newman said. “It’s unlikely to ever fully replace the need for in-person hospital reviews, but it will likely reduce their frequency.”

The results of the study right now suggest cutting the test to one minute has no detrimental effect on its outcome or accuracy, and that patients are far more likely to run the test regularly if they’re able to do so at home. “It’s likely that the upfront costs of wearables [to a hospital] may be offset by the longer term reduction in hospital visits,” Dr. Newman said. If that turns out to be right, it means clinicians can better focus their time and efforts where their expertise is more valuable.

This article originally appeared on Engadget at https://www.engadget.com/dr-garmin-will-see-you-now-160013340.html?src=rss

© Garmin

Product image of a Garmin Venu 2 on a white background.
❌
❌